Newron reports first-half loss amid Evenamide R&D surge

Newron, a Swiss-listed Italian biopharma company, reported a first-half loss of 16.4 million euros in the latest quarter, driven by a more than doubling of research and development expenses to 14.6 million euros compared with the prior year. Revenue fell to 3.2 million euros from 11.9 million euros in the same period last year, reflecting reduced contributions from milestone payments tied to licensing agreements with EA Pharma (a subsidiary of Eisai) and Myung In Pharm, which had previously bolstered earnings. The company’s cash reserves stood at 32.9 million euros as of June 30, 2026, up from 28.9 million euros at year-end 2025, though liquidity remains a focus amid ongoing development costs.